CUE.OQ
Latest Trade
--Change
--(--)Today's Range
-
--52 Week Range
-
--As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | -- |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 2.72 |
Today's High | -- |
Today's Low | -- |
52 Week High | -- |
52 Week Low | -- |
Shares Out (MIL) | 22.99 |
Market Cap (MIL) | 268.80 |
Forward P/E | -6.80 |
Dividend (Yield %) | -- |
Cue Biopharma Reports Third Quarter 2019 Financial Results
Cue Biopharma Qtrly Loss Per Share $0.31
Cue Biopharma Promotes Dr. Anish Suri To President And CSO
Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.
Industry
Biotechnology & Drugs
Executive Leadership
Barry J. Simon
Independent Chairman of the Board
Anish Suri
President, Chief Scientific Officer
Daniel R. Passeri
Chief Executive Officer, Director
Rodolfo J. Chaparro
Executive Vice President - Head of Immunology
Ronald D. Seidel
Executive Vice President - Head of Research and Development
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 98.12 |
Price To Book (MRQ) | 9.94 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -106.17 |
Return on Equity (TTM) | -87.76 |
* PETER APPEL REPORTS A PASSIVE STAKE OF 7.6 PERCENT IN CUE BIOPHARMA INC AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2BWquxU) Further company coverage:
* MARK STROME REPORTS A 5.7 PERCENT PASSIVE STAKE IN CUE BIOPHARMA INC AS OF DECEMBER 27, 2017- SEC FILING Source: (http://bit.ly/2AIDG48) Further company coverage:
* CUE BIOPHARMA INC SEES IPO OF UP TO 8 MILLION SHARES OF ITS COMMON STOCK PRICED AT $7.50 PER SHARE - SEC FILING
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.